Patents Examined by Raymond J. Henley, III
  • Cannabinoids for use in suppressing cancer stem cells
    Patent number: 11583506
    Abstract: It is disclosed a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof: wherein R1 is a linear alkyl group of 3 or 5 carbon atoms, and R2 is: and a pharmaceutical composition comprising the same, for use in the treatment of a disease whose treatment benefits from inhibiting or reducing Notch1 expression levels in cells, and/or benefits from inhibiting or reducing Notch1 levels in cells, and/or benefits from inhibiting or reducing Notch1 signaling dependent proteins levels in cells. As a consequence, present invention also relates to said compound of formula (I), and to the pharmaceutical composition comprising the same, for use in suppressing cancer stem cells, as well as, for use in reducing solid tumor development, metastasis or chemo/radio-resistance, promoted by cancer stem cells.
    Type: Grant
    Filed: October 24, 2022
    Date of Patent: February 21, 2023
    Inventors: Jon Peñarando Sáez, Juan Diego Unciti Broceta, Eduardo Muñoz Blanco
  • Dual antagonist of PGD/DPr2 and Thromboxane A/TPr receptors and use for treatment of maladaptive immune response or thrombotic diathesis
    Patent number: 11583517
    Abstract: The present invention relates to a pharmaceutical composition for treatment of a disease or condition characterized by or associated with stimulation of both DPr2 and TPr signaling, said composition comprising an effective amount of a dual receptor antagonist of DPr2 for prostaglandin D2 and TPr for thromboxane A2 and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 30, 2021
    Date of Patent: February 21, 2023
    Assignee: APPLIED MEDICAL TECHNOLOGIES LLC
    Inventors: Ajay Gupta, Kate Chander Chiang
  • Treatment of prostate cancer
    Patent number: 11583526
    Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: February 21, 2023
    Assignees: Myovant Sciences GmbH, Takeda Pharmaceutical Company Limited
    Inventors: Vijaykumar Reddy Rajasekhar, Brendan Mark Johnson, David B. MacLean, Lynn Seely, Paul N. Mudd, Jr.
  • Methods of identifying and treating patients with HIF-2 inhibitor resistance
    Patent number: 11576889
    Abstract: The present disclosure provides methods of identifying patients who have partial or total resistance to HIF-2 inhibitors or who develop partial or total resistance to HIF-2 inhibitors after treatment and providing suitable treatment to these patients.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: February 14, 2023
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: James B. Brugarolas, Haley Hill, Tao Wang
  • Use of VNN1 as a biomarker and a therapeutic target in sarcomas
    Patent number: 11579147
    Abstract: Sarcomas are rare malignant tumors arising from the mesenchymal tissues at all body sites. The inventors show that in a mouse model of p16/p19 deficiency prone to tumor development, the absence of the mouse pantetheinase Vnn1 enhances the frequency of aggressive fibrosarcomas. They also show that reintroduction of a catalytically active form of the Vnn1 pantetheinase limits tumor growth in vivo. Interestingly, VNN1 expression in human sarcomas is associated with reduced aggressiveness and lower risk of metastatic relapse in patients. In conclusion, Vnn1 represents a novel marker of sarcoma and may modulate tumor aggressiveness by sustaining myofibroblast cell differentiation, thereby limiting evolution towards undifferentiated tumors. The present invention relates to the use of Vnn1 as a biomarker and a therapeutic target in sarcomas.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: February 14, 2023
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université d'Aix Marseille, Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard, Centre Leon Bernard
    Inventors: Philippe Naquet, Franck Galland, Virginie Millet, Jean-Yves Blay, Caroline Giessner
  • Methods for making and using endoxifen
    Patent number: 11572334
    Abstract: The present disclosure provides industrially scalable methods of making (Z)-endoxifen or a salt thereof, crystalline forms of endoxifin, and compositions comprising them. The present disclosure also provides methods for treating hormone-dependent breast and hormone-dependent reproductive tract disorders.
    Type: Grant
    Filed: January 20, 2022
    Date of Patent: February 7, 2023
    Assignee: ATOSSA THERAPEUTICS, INC.
    Inventors: Steven C. Quay, Yao-Lin Sun, LungHu Wang, ChangJung Wu, ChuanDer Huang
  • Therapy for transthyretin-associated amyloidosis
    Patent number: 11564899
    Abstract: It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: January 31, 2023
    Assignee: SOM Innovation Biotech, S.L.
    Inventors: Marc Centellas Casado, Raúl Insa Boronat, Nuria Reig Bolaño, Núria Gavaldà Batalla
  • Extended duration local anesthetic formulation
    Patent number: 11564902
    Abstract: An extended duration anesthetic includes a short duration local anesthetic in a dilute solution and a long duration local anesthetic. The long duration local anesthetic is maintained in a powdered form until the time of administration. Premeasured quantities of the dilute solution and powdered long duration local anesthetic in a kit allow for quick preparation of a solution with desired concentrations of both short duration local anesthetic and long duration local anesthetic at the time of administration.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: January 31, 2023
    Assignee: Ventis Pharma
    Inventors: Jeremy Poulsen, Louis Stanfield, Lawrence Volz
  • Methods of treating cancer with farnesyltransferase inhibitors
    Patent number: 11541045
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma (“PTCL”), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: January 3, 2023
    Assignee: Kura Oncology, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Methods and compositions for the treatment of neurological diseases and syndromes of aging
    Patent number: 11541022
    Abstract: Disclosed are methods for the removal of plaques containing amyloid beta, protecting the brain from amyloid beta toxicity, and restoring neurological function by the expansion of neural stem cell pools and improving mitochondrial health.
    Type: Grant
    Filed: May 2, 2022
    Date of Patent: January 3, 2023
    Inventor: Louis Dischler
  • Crenolanib for treating TRK kinase associated proliferative disorders
    Patent number: 11524006
    Abstract: The present invention includes methods for treating TRKA, TRKB, and/or TRKC driven proliferative disorder in a subject comprising administering to the subject a therapeutically effective amount of crenolanib, wherein the subject has a proliferative disorder with overexpression, activation, amplification, or mutation of TRKA, TRKB, and/or TRKC kinase.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: December 13, 2022
    Assignee: AROG PHARMACEUTICALS, INC.
    Inventor: Vinay K. Jain
  • Treatment of a disease of the gastrointestinal tract with an immunosuppressant
    Patent number: 11523772
    Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an immunosuppressant.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: December 13, 2022
    Assignee: BIORA THERAPEUTICS, INC.
    Inventors: Mitchell Lawrence Jones, Sharat Singh, Christopher Loren Wahl, Harry Stylli
  • Inhibitors of cysteine proteases and methods of use thereof
    Patent number: 11524940
    Abstract: The disclosure provides compounds with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: December 13, 2022
    Assignee: Pardes Biosciences, Inc.
    Inventors: Lee D. Arnold, Andy Jennings, Walter Keung
  • Use of microvesicles in analyzing nucleic acid profiles
    Patent number: 11519036
    Abstract: The invention concerns gene signatures obtained from microvesicles and a method of applying these gene signatures in helping to determine a biological condition. The determination of a biological condition may aid, for example, the diagnosis, prognosis, and therapy treatment selection for disease in a subject.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: December 6, 2022
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Mikkel Noerholm, Johan Karl Olov Skog, Xandra O. Breakefield, Bob Carter
  • Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
    Patent number: 11517553
    Abstract: A formulation, including: (a) a first medicament, wherein the first medicament includes an isothiocyanate functional compound/surfactant; and (b) a second medicament, wherein the second medicament includes an antineoplastic agent, such as a cytotoxic antineoplastic agent and/or a targeted antineoplastic agent.
    Type: Grant
    Filed: September 8, 2020
    Date of Patent: December 6, 2022
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof
    Patent number: 11518747
    Abstract: The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof. The present invention also provides compositions comprising the crystalline form and/or the amorphous form, therapeutic uses of the crystalline forms and/or the amorphous forms, and the compositions thereof.
    Type: Grant
    Filed: April 28, 2022
    Date of Patent: December 6, 2022
    Assignee: ESSA Pharma, Inc.
    Inventors: Han-Jie Zhou, Peter Virsik
  • Water soluble compositions comprising purified cannabinoids
    Patent number: 11510897
    Abstract: This disclosure relates to new compositions and methods for making cannabinoid formulations. In one embodiment, this disclosure provides water soluble compositions comprising a first purified cannabinoid and Vitamin E TPGS. In one embodiment, the disclosure herein comprises a method of making powders comprising heatings material to a first temperature and a second temperature.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: November 29, 2022
    Assignee: CANOPY GROWTH CORPORATION
    Inventor: Kurt Aron Levy
  • Methods and therapeutics to regulate hydrogen sulfide bioavailability
    Patent number: 11510925
    Abstract: The presently claimed invention is related to compositions and methods for treating H2S related diseases comprising administering a pharmacologically effective amount of pharmaceutical composition containing a first therapeutic, wherein the first therapeutic includes one of an ATR kinase inhibitor and an ATR kinase promotor. According to further embodiments the H2S related disease is one of cancer, cardiovascular disease, acute inflammation, chronic inflammation, and neurological disease.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: November 29, 2022
    Assignee: Board of Supervisors of Louisiana State University
    Inventors: Christopher G. Kevil, Rodney Shackelford
  • Methods and compositions utilizing RRx-001 combination therapy for radioprotection
    Patent number: 11510901
    Abstract: Provided herein are therapeutic methods, kits, and pharmaceutical compositions for protecting a subject from radiation using a therapeutic agent selected from the group consisting of RRx-OO1 and a pharmaceutically acceptable salt thereof. One exemplary therapeutic method involves administering RRx-OO1 to the subject prior to the subject being exposed to the radiation, in order to protect the subject against radiation, such as ionizing radiation containing ?-rays, ?-rays, ?-rays, neutron radiation, or a combination thereof.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: November 29, 2022
    Assignee: EpicentRx, Inc.
    Inventors: Bryan T. Oronsky, Arnold Oronsky, Tony R. Reid
  • Method of using biomarkers and clinical variables for predicting chemotherapy benefit
    Patent number: 11505832
    Abstract: Provided herein are methods for predicting chemotherapy benefit. The invention predicts chemotherapy benefit based on the expression analysis of biomarkers, e.g., RNA biomarker transcription analysis, taken from a tumor sample. The biomarker expression data can be combined with clinical variables, e.g., tumor size and nodal status, to generate a profile that predicts the benefit of including chemotherapy as a treatment decision.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: November 22, 2022
    Assignee: MYRIAD GENETICS, INC.
    Inventors: Alexander Gutin, Julia Reid, Ralf Kronenwett, Marsel Scheer